3205 Stock Overview
Sagittarius Life Science Corp researches, develops, and sells Chinese and western medicines, and health food products in Taiwan and Asia.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Sagittarius Life Science Corp Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$41.15 |
52 Week High | NT$60.90 |
52 Week Low | NT$39.60 |
Beta | 0.68 |
1 Month Change | -9.86% |
3 Month Change | -21.17% |
1 Year Change | 3.39% |
3 Year Change | 28.19% |
5 Year Change | -18.03% |
Change since IPO | -65.67% |
Recent News & Updates
Shareholder Returns
3205 | TW Personal Products | TW Market | |
---|---|---|---|
7D | -3.2% | 2.2% | -0.3% |
1Y | 3.4% | -8.2% | 25.8% |
Return vs Industry: 3205 exceeded the TW Personal Products industry which returned -8.2% over the past year.
Return vs Market: 3205 underperformed the TW Market which returned 25.8% over the past year.
Price Volatility
3205 volatility | |
---|---|
3205 Average Weekly Movement | 3.3% |
Personal Products Industry Average Movement | 3.5% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 8.1% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 3205's share price has been volatile over the past 3 months.
Volatility Over Time: 3205's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | n/a | n/a | https://www.naturalbiokey.com |
Sagittarius Life Science Corp researches, develops, and sells Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Sagittarius Life Science Corp Fundamentals Summary
3205 fundamental statistics | |
---|---|
Market cap | NT$1.34b |
Earnings (TTM) | -NT$55.04m |
Revenue (TTM) | NT$440.46m |
3.0x
P/S Ratio-24.3x
P/E RatioIs 3205 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
3205 income statement (TTM) | |
---|---|
Revenue | NT$440.46m |
Cost of Revenue | NT$368.98m |
Gross Profit | NT$71.48m |
Other Expenses | NT$126.52m |
Earnings | -NT$55.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.69 |
Gross Margin | 16.23% |
Net Profit Margin | -12.50% |
Debt/Equity Ratio | 0% |
How did 3205 perform over the long term?
See historical performance and comparison